{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:55:06Z","timestamp":1793386506057,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11916-024-01213-x","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T12:01:27Z","timestamp":1712404887000},"page":"641-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Triptans in the Acute Migraine Management of Children and Adolescents: An Update"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-1736","authenticated-orcid":false,"given":"Jessica Hauser","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi K.","family":"Blume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"1","key":"1213_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","volume":"24","author":"A Onofri","year":"2023","unstructured":"Onofri A, Pensato U, Rosignoli C, et al. Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):8. https:\/\/doi.org\/10.1186\/s10194-023-01541-0.","journal-title":"J Headache Pain"},{"issue":"10","key":"1213_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11916-020-00892-6","volume":"24","author":"V Nieswand","year":"2020","unstructured":"Nieswand V, Richter M, Gossrau G. Epidemiology of headache in children and adolescents-another type of pandemia. Curr Pain Headache Rep. 2020;24(10):62. https:\/\/doi.org\/10.1007\/s11916-020-00892-6.","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"1213_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/0883073808327831","volume":"24","author":"TM Lateef","year":"2009","unstructured":"Lateef TM, Merikangas KR, He J, et al. Headache in a national sample of American children: prevalence and comorbidity. J Child Neurol. 2009;24(5):536\u201343. https:\/\/doi.org\/10.1177\/0883073808327831.","journal-title":"J Child Neurol"},{"issue":"12","key":"1213_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1469-8749.2010.03793.x","volume":"52","author":"I Abu-Arafeh","year":"2010","unstructured":"Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088\u201397. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03793.x.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1213_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s10194-023-01634-w","volume":"24","author":"Y Yang","year":"2023","unstructured":"Yang Y, Cao Y. Rising trends in the burden of migraine and tension-type headache among adolescents and young adults globally, 1990 to 2019. J Headache Pain. 2023;24(1):94. https:\/\/doi.org\/10.1186\/s10194-023-01634-w.","journal-title":"J Headache Pain"},{"issue":"9","key":"1213_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41582-018-0042-7","volume":"14","author":"SL Orr","year":"2018","unstructured":"Orr SL, Kabbouche MA, O\u2019Brien HL, Kacperski J, Powers SW, Hershey AD. Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol. 2018;14(9):515\u201327. https:\/\/doi.org\/10.1038\/s41582-018-0042-7.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1213_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/head.12042","volume":"53","author":"S Leung","year":"2013","unstructured":"Leung S, Bulloch B, Young C, et al. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013;53(3):171\u20137. https:\/\/doi.org\/10.1111\/head.12042.","journal-title":"Headache"},{"issue":"12","key":"1213_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/jamapediatrics.2022.3940","volume":"176","author":"K Falla","year":"2022","unstructured":"Falla K, Kuziek J, Mahnaz SR, Noel M, Ronksley PE, Orr SL. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: a systematic review and meta-analysis. JAMA Pediatr. 2022;176(12):1176\u201387. https:\/\/doi.org\/10.1001\/jamapediatrics.2022.3940.","journal-title":"JAMA Pediatr"},{"issue":"7","key":"1213_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.14712","volume":"4","author":"SW Powers","year":"2021","unstructured":"Powers SW, Coffey CS, Chamberlin LA, et al. Prevalence of headache days and disability 3 years after participation in the childhood and adolescent migraine prevention medication trial. JAMA Netw Open. 2021;4(7):1\u201314. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.14712.","journal-title":"JAMA Netw Open"},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pediatrneurol.2023.05.019","volume":"146","author":"M Canfora","year":"2023","unstructured":"Canfora M, Pallotto IK, Davis JK, et al. More than a headache: lived experience of migraine in youth. Pediatr Neurol. 2023;146:79\u201384. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.05.019.","journal-title":"Pediatr Neurol"},{"key":"1213_CR11","doi-asserted-by":"publisher","unstructured":"Abu-Arafeh I. Headache and psychological comorbidities: an appraisal of the evidence. J Clin Med. 2023;12(7). https:\/\/doi.org\/10.3390\/jcm12072683.","DOI":"10.3390\/jcm12072683"},{"issue":"6395","key":"1213_CR12","doi-asserted-by":"publisher","first-page":"eaap8757","DOI":"10.1126\/science.aap8757","volume":"360","author":"V Anttila","year":"2018","unstructured":"Brainstorm Consortium, Anttila V, Bulik-Sullivan B, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395):eaap8757. https:\/\/doi.org\/10.1126\/science.aap8757.","journal-title":"Science"},{"issue":"11","key":"1213_CR13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1213_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11916-013-0341-z","volume":"17","author":"C W\u00f6ber-Bing\u00f6l","year":"2013","unstructured":"W\u00f6ber-Bing\u00f6l C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341. https:\/\/doi.org\/10.1007\/s11916-013-0341-z.","journal-title":"Curr Pain Headache Rep"},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.07.015","volume":"89","author":"MC Perry","year":"2018","unstructured":"Perry MC, Yaeger SK, Toto RL, Suresh S, Hickey RW. A modern epidemic: increasing pediatric emergency department visits and admissions for headache. Pediatr Neurol. 2018;89:19\u201325. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2018.07.015.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1213_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pediatrneurol.2012.06.001","volume":"47","author":"AA Gelfand","year":"2012","unstructured":"Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatr Neurol. 2012;47(4):233\u201341. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.06.001.","journal-title":"Pediatr Neurol"},{"key":"1213_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fneur.2019.00886","volume":"10","author":"U Raucci","year":"2019","unstructured":"Raucci U, Della Vecchia N, Ossella C, et al. Management of childhood headache in the emergency department. Review of the literature. Front Neurol. 2019;10:886. https:\/\/doi.org\/10.3389\/fneur.2019.00886. Published 2019 Aug 23.","journal-title":"Front Neurol"},{"issue":"1","key":"1213_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2014.02.022","volume":"51","author":"JM Dooley","year":"2014","unstructured":"Dooley JM, Augustine HF, Brna PM, Digby AM. The prognosis of pediatric headaches - A 30-year follow-up study. Pediatr Neurol. 2014;51(1):85\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.02.022.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1213_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pediatrneurol.2015.05.013","volume":"53","author":"M Galinski","year":"2015","unstructured":"Galinski M, Sidhoum S, Cimerman P, Perrin O, Annequin D, Tourniaire B. Early diagnosis of migraine necessary in children: 10-year follow-up. Pediatr Neurol. 2015;53(4):319\u201323. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.05.013.","journal-title":"Pediatr Neurol"},{"issue":"9","key":"1213_CR20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/head.14396","volume":"62","author":"SL Orr","year":"2022","unstructured":"Orr SL, Shapiro RE. The elephant in the room: How the underfunding of headache research stunts the field. Headache. 2022;62(9):1234\u20138. https:\/\/doi.org\/10.1111\/head.14396.","journal-title":"Headache"},{"issue":"6","key":"1213_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","volume":"60","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. Drugs. 2000;60(6):1259\u201387. https:\/\/doi.org\/10.2165\/00003495-200060060-00003.","journal-title":"Drugs"},{"issue":"5","key":"1213_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/J.1526-4610.2008.01097.X","volume":"48","author":"PPA Humphrey","year":"2008","unstructured":"Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008;48(5):685\u20137. https:\/\/doi.org\/10.1111\/J.1526-4610.2008.01097.X.","journal-title":"Headache"},{"issue":"1\u20132","key":"1213_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","volume":"115","author":"AH Ahn","year":"2005","unstructured":"Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1\u20132):1\u20134. https:\/\/doi.org\/10.1016\/j.pain.2005.03.008.","journal-title":"Pain"},{"issue":"1","key":"1213_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109.","journal-title":"Ann Neurol"},{"issue":"3","key":"1213_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/J.1468-2982.2005.00836.X","volume":"25","author":"G Juhasz","year":"2005","unstructured":"Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179\u201383. https:\/\/doi.org\/10.1111\/J.1468-2982.2005.00836.X.","journal-title":"Cephalalgia"},{"issue":"7","key":"1213_CR26","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u201366. https:\/\/doi.org\/10.1007\/s00415-023-11706-1.","journal-title":"J Neurol"},{"issue":"2","key":"1213_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/S13311-018-0615-6","volume":"15","author":"M Vila-Pueyo","year":"2018","unstructured":"Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291\u2013303. https:\/\/doi.org\/10.1007\/S13311-018-0615-6.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"1213_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ana.10066","volume":"50","author":"PJ Goadsby","year":"2001","unstructured":"Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol. 2001;50(6):804\u20137. https:\/\/doi.org\/10.1002\/ana.10066.","journal-title":"Ann Neurol"},{"issue":"1","key":"1213_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01365-w","volume":"23","author":"A Wiggers","year":"2022","unstructured":"Wiggers A, Ashina H, Hadjikhani N, et al. Brain barriers and their potential role in migraine pathophysiology. J Headache Pain. 2022;23(1):1\u201310. https:\/\/doi.org\/10.1186\/s10194-021-01365-w.","journal-title":"J Headache Pain"},{"issue":"3","key":"1213_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/neurolint15030067","volume":"15","author":"H Ple\u0219","year":"2023","unstructured":"Ple\u0219 H, Florian IA, Timis TL, et al. Migraine: advances in the pathogenesis and treatment. Neurol Int. 2023;15(3):1052\u2013105. https:\/\/doi.org\/10.3390\/neurolint15030067.","journal-title":"Neurol Int"},{"issue":"SUPPL. 9","key":"1213_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/J.1468-2982.1989.TB00069.X","volume":"9","author":"PPA Humphrey","year":"1989","unstructured":"Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(SUPPL. 9):23\u201333. https:\/\/doi.org\/10.1111\/J.1468-2982.1989.TB00069.X.","journal-title":"Cephalalgia"},{"key":"1213_CR32","doi-asserted-by":"publisher","unstructured":"Humphrey PPA. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol. 1991;238(1 Supplement). https:\/\/doi.org\/10.1007\/BF01642905.","DOI":"10.1007\/BF01642905"},{"issue":"4","key":"1213_CR33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1476-5381.1988.tb11630.x","volume":"94","author":"PP Humphrey","year":"1988","unstructured":"Humphrey PP, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988;94(4):1123\u201332. https:\/\/doi.org\/10.1111\/j.1476-5381.1988.tb11630.x.","journal-title":"Br J Pharmacol"},{"key":"1213_CR34","doi-asserted-by":"publisher","unstructured":"Pini LA, Brovia D. Different characteristics of triptans. J Headache Pain. 2004;5(SUPPL. 2). https:\/\/doi.org\/10.1007\/s10194-004-0122-5.","DOI":"10.1007\/s10194-004-0122-5"},{"key":"1213_CR35","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:487\u201399.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000008095. Updated guidelines on acute care, thoughtful systematic review, and endorsed by the American Academy of Pediatrics and Child Neurology Society.","DOI":"10.1212\/WNL.0000000000008095"},{"issue":"5","key":"1213_CR36","doi-asserted-by":"publisher","first-page":"20192762","DOI":"10.1542\/peds.2019-2762","volume":"144","author":"SOF Endorsement","year":"2019","unstructured":"Endorsement SOF. Acute treatment of migraine in children and adolescents. Pediatrics. 2019;144(5):20192762. https:\/\/doi.org\/10.1542\/peds.2019-2762.","journal-title":"Pediatrics"},{"key":"1213_CR37","unstructured":"Practice guideline update: acute treatment of migraine in children and adolescents. https:\/\/www.aan.com\/Guidelines\/home\/GuidelineDetail\/966. Accessed 30 Jan 2024."},{"issue":"1","key":"1213_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"J Olesen","year":"2018","unstructured":"Olesen J. Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","journal-title":"Cephalalgia"},{"issue":"5","key":"1213_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B\/1D agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04078.x.","journal-title":"Headache"},{"key":"1213_CR40","unstructured":"GlaxoSmithKline.\u00a0Imitrex Tablets (Sumatriptan succinate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013. www.fda.gov\/medwatch."},{"key":"1213_CR41","unstructured":"Maxalt Tablets (Rizatriptan Benzoate). [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2007"},{"issue":"2","key":"1213_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1474-4422(09)70303-5","volume":"9","author":"AD Hershey","year":"2010","unstructured":"Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9(2):190\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(09)70303-5.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1213_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/J.1468-2982.2007.01288.X","volume":"27","author":"LJ Stovner","year":"2007","unstructured":"Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193\u2013210. https:\/\/doi.org\/10.1111\/J.1468-2982.2007.01288.X.","journal-title":"Cephalalgia"},{"issue":"3","key":"1213_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1526-4610.2005.05050.x","volume":"45","author":"DW Lewis","year":"2005","unstructured":"Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005;45(3):232\u20139. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05050.x.","journal-title":"Headache"},{"issue":"7","key":"1213_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1468-2982.2008.01788.x","volume":"29","author":"TW Ho","year":"2009","unstructured":"Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: Pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29(7):711\u20138. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01788.x.","journal-title":"Cephalalgia"},{"key":"1213_CR46","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13312-023-2968-0","volume":"60","author":"R Chanchlani","year":"2023","unstructured":"\u2022 Chanchlani R, Agrawal A, Janjua D, Hafsa SN. The efficacy of different triptans for the treatment of acute headache in pediatric migraine: a systematic review. Indian Pediatr. 2023;60:663\u201371. Most recent systematic review incorporating most recent studies on triptans in pediatric migraine.","journal-title":"Indian Pediatr"},{"issue":"3","key":"1213_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamapediatrics.2013.872","volume":"167","author":"H Sun","year":"2013","unstructured":"Sun H, Bastings E, Temeck J, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr. 2013;167(3):243\u20139. https:\/\/doi.org\/10.1001\/jamapediatrics.2013.872.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"1213_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/J.1526-4610.2006.00313.X","volume":"46","author":"AD Rothner","year":"2006","unstructured":"Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46(1):101\u20139. https:\/\/doi.org\/10.1111\/J.1526-4610.2006.00313.X.","journal-title":"Headache"},{"issue":"7","key":"1213_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1046\/j.1468-2982.2003.00528.x","volume":"23","author":"L Bendtsen","year":"2003","unstructured":"Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003;23(7):487\u201390. https:\/\/doi.org\/10.1046\/j.1468-2982.2003.00528.x.","journal-title":"Cephalalgia"},{"issue":"1","key":"1213_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1526-4610.2002.02013.x","volume":"42","author":"P Winner","year":"2002","unstructured":"Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42(1):49\u201355. https:\/\/doi.org\/10.1046\/j.1526-4610.2002.02013.x.","journal-title":"Headache"},{"key":"1213_CR51","doi-asserted-by":"publisher","first-page":"105853","DOI":"10.1016\/j.clineuro.2020.105853","volume":"195","author":"G Wang","year":"2020","unstructured":"Wang G, Tan T, Liu Y, Hong P. Drugs for acute attack of pediatric migraine: a network meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2020;195:105853. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105853.","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"1213_CR52","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11916-013-0342-y","volume":"17","author":"S Evers","year":"2013","unstructured":"Evers S. The efficacy of triptans in childhood and adolescence migraine. Curr Pain Headache Rep. 2013;17(7):342. https:\/\/doi.org\/10.1007\/s11916-013-0342-y.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"1213_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40272-013-0019-3","volume":"15","author":"\u00c7 W\u00f6ber-Bing\u00f6l","year":"2013","unstructured":"W\u00f6ber-Bing\u00f6l \u00c7. Pharmacological treatment of acute migraine in adolescents and children. Pediatric Drugs. 2013;15(3):235\u201346. https:\/\/doi.org\/10.1007\/s40272-013-0019-3.","journal-title":"Pediatric Drugs"},{"issue":"4","key":"1213_CR54","doi-asserted-by":"publisher","first-page":"CD005220","DOI":"10.1002\/14651858.CD005220.pub2","volume":"4","author":"L Richer","year":"2016","unstructured":"Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4(4):CD005220. https:\/\/doi.org\/10.1002\/14651858.CD005220.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7650","key":"1213_CR55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ (Clinical research ed.)"},{"key":"1213_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:4\u201310. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1213_CR57","volume-title":"Clinical practice guideline process manual","author":"AAN (American Academy of Neurology)","year":"2011","unstructured":"AAN (American Academy of Neurology). Clinical practice guideline process manual. 2011th ed. St. Paul, MN: The American Academy of Neurology; 2011.","edition":"2011"},{"key":"1213_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clineuro.2017.01.009","volume":"154","author":"P Hong","year":"2017","unstructured":"Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg. 2017;154:74\u20138. https:\/\/doi.org\/10.1016\/j.clineuro.2017.01.009.","journal-title":"Clin Neurol Neurosurg"},{"key":"1213_CR59","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Yonker ME, McVige J, Zeitlin L, Visser H. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension. Headache. 2022;62(9):1207\u201317.\u00a0https:\/\/doi.org\/10.1111\/head.14391. First trial in children 6\u201311 to study zolmitriptan. Notable findings include evidence for headache relief with zolmitriptan in children 6-11, although this was a secondary endpoint and no statistical different found in primary outcome of pain freedom influenced by early termination with slow enrollment during COVID-19 pandemic.\u00a0","DOI":"10.1111\/head.14391"},{"issue":"2","key":"1213_CR60","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1542\/peds.2014-2432","volume":"135","author":"RG Bachur","year":"2015","unstructured":"Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015;135(2):232\u20138. https:\/\/doi.org\/10.1542\/peds.2014-2432.","journal-title":"Pediatrics"},{"issue":"1","key":"1213_CR61","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1542\/PEDS.2009-2337","volume":"126","author":"LP Richer","year":"2010","unstructured":"Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126(1):e150\u20135. https:\/\/doi.org\/10.1542\/PEDS.2009-2337.","journal-title":"Pediatrics"},{"issue":"8","key":"1213_CR62","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/0883073810397631","volume":"26","author":"G Legault","year":"2011","unstructured":"Legault G, Eisman H, Shevell MI. Treatment of pediatric status migrainosus: can we prevent the \u201cbounce back.\u201d J Child Neurol. 2011;26(8):949\u201355. https:\/\/doi.org\/10.1177\/0883073810397631.","journal-title":"J Child Neurol"},{"issue":"3","key":"1213_CR63","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ajem.2010.12.020","volume":"30","author":"ED Trottier","year":"2012","unstructured":"Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012;30(3):456\u201363. https:\/\/doi.org\/10.1016\/j.ajem.2010.12.020.","journal-title":"Am J Emerg Med"},{"key":"1213_CR64","doi-asserted-by":"publisher","unstructured":"\u2022 Genadry KC, Monuteaux MC, Neuman MI, Lowe DA, Lee LK. Disparities and trends in migraine management in pediatric emergency departments, 2009\u201319. Acad Pediatr. 2022. https:\/\/doi.org\/10.1016\/j.acap.2022.04.007. Most recent investigation of trends of medication use for the treatment of migraine in pediatric emergency departments.","DOI":"10.1016\/j.acap.2022.04.007"},{"issue":"4","key":"1213_CR65","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s0196-0644(95)70259-8","volume":"25","author":"BE Akpunonu","year":"1995","unstructured":"Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25(4):464\u20139. https:\/\/doi.org\/10.1016\/s0196-0644(95)70259-8.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"1213_CR66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0735-6757(02)42256-5","volume":"21","author":"JT Meredith","year":"2003","unstructured":"Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21(3):173\u20135. https:\/\/doi.org\/10.1016\/S0735-6757(02)42256-5.","journal-title":"Am J Emerg Med"},{"key":"1213_CR67","doi-asserted-by":"publisher","unstructured":"\u2022 Hauser Chatterjee J, Hartford EA, Law E, Barry D, Blume H. Sumatriptan as a first-line treatment for headache in the pediatric emergency department. Pediatr Neurol. 2023;142:68\u201375. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.01.016. Retrospective study summarizing single-center experience using triptan in the pediatric emergency department. Results suggest there may be a reduced need for IV management, shorter length of stays, and decrease in charges with IN sumatriptan as a first line treatment in the ED.","DOI":"10.1016\/j.pediatrneurol.2023.01.016"},{"issue":"10","key":"1213_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):1\u201315. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1213_CR69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00023210-200519040-00006","volume":"19","author":"MP Curran","year":"2005","unstructured":"Curran MP, Evans HC, Wagstaff AJ. Intranasal sumatriptan: in adolescents with migraine. CNS Drugs. 2005;19(4):335\u20136. https:\/\/doi.org\/10.2165\/00023210-200519040-00006.","journal-title":"CNS Drugs"},{"issue":"6","key":"1213_CR70","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-2125.2010.03881.x","volume":"71","author":"J Lindkvist","year":"2011","unstructured":"Lindkvist J, Airaksinen M, Kaukonen AM, Klaukka T, Hoppu K. Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994\u20132007. Br J Clin Pharmacol. 2011;71(6):929\u201335. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03881.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1213_CR71","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.pediatrneurol.2014.06.018","volume":"51","author":"A Johnson","year":"2014","unstructured":"Johnson A, Bickel J, Lebel A. Pediatric migraine prescription patterns at a large academic hospital. Pediatr Neurol. 2014;51(5):706\u201312. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.06.018.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1213_CR72","doi-asserted-by":"publisher","first-page":"382","DOI":"10.18553\/JMCP.2017.23.3.382","volume":"23","author":"LL Lai","year":"2017","unstructured":"Lai LL, Koh L, Ho JAC, Ting A, Obi A. Off-label prescribing for children with migraines in U.S. ambulatory care settings. J Manag Care Spec Pharm. 2017;23(3):382\u20137. https:\/\/doi.org\/10.18553\/JMCP.2017.23.3.382.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1213_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1542\/peds.106.5.989","volume":"106","author":"P Winner","year":"2000","unstructured":"Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989\u201397. https:\/\/doi.org\/10.1542\/peds.106.5.989.","journal-title":"Pediatrics"},{"issue":"2","key":"1213_CR74","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1526-4610.2006.00339.x","volume":"46","author":"P Winner","year":"2006","unstructured":"Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46(2):212\u201322. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00339.x.","journal-title":"Headache"},{"issue":"6","key":"1213_CR75","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1212\/01.wnl.0000115105.05966.a7","volume":"62","author":"K Ahonen","year":"2004","unstructured":"Ahonen K, H\u00e4m\u00e4l\u00e4inen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology. 2004;62(6):883\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000115105.05966.a7.","journal-title":"Neurology"},{"issue":"1","key":"1213_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):1\u201310. https:\/\/doi.org\/10.1186\/s10194-022-01502-z.","journal-title":"J Headache Pain"},{"issue":"18","key":"1213_CR77","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1212\/WNL.0000000000207677","volume":"101","author":"JH Vanderpluym","year":"2023","unstructured":"Vanderpluym JH, Victorio MCC, Oakley CB, Rastogi RG, Orr SL. Beyond the guidelines: a narrative review of treatments on the horizon for migraine in children and adolescents. Neurology. 2023;101(18):788\u201397. https:\/\/doi.org\/10.1212\/WNL.0000000000207677.","journal-title":"Neurology"},{"issue":"1","key":"1213_CR78","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1038\/s41598-022-12545-2","volume":"12","author":"A Olesen","year":"2022","unstructured":"Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022;12(1):8487. https:\/\/doi.org\/10.1038\/s41598-022-12545-2.","journal-title":"Sci Rep"},{"issue":"3","key":"1213_CR79","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1212\/CON.0000000000000993","volume":"27","author":"C Szperka","year":"2021","unstructured":"Szperka C. Headache in children and adolescents. CONTINUUM Lifelong Learn Neurol. 2021;27(3):703\u201331. https:\/\/doi.org\/10.1212\/CON.0000000000000993.","journal-title":"CONTINUUM Lifelong Learn Neurol"},{"key":"1213_CR80","unstructured":"US Food and Drug Administration. Pediatric research equity act of 2003. Public Law. 2017;108155.\u00a0https:\/\/congress.gov\/108\/plaws\/publ155\/PLAW-108publ155.pdf. Accessed 20 Dec 2023."}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-024-01213-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:13:28Z","timestamp":1721466808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-024-01213-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s11916-024-01213-x","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"9 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict Interest"}}]}}